Future Directions and Unmet Needs in Relapsed/Refractory MCL
A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.
EP: 1.Current Treatment Options in First-line FL
EP: 2.ASH 2023 Updates on Frontline Therapies in FL
EP: 3.Current Treatment Options in Second-line FL
EP: 4.CAR T-cells as Third-line and Beyond Therapy for FL
EP: 5.Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL
EP: 6.Tazemetostat as Third-line and Beyond Therapy for FL
EP: 7.Zanubrutinib as Third-Line and Beyond Therapy for FL
EP: 8.Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL
EP: 9.Choosing CAR T-cells as Third-line and Beyond Therapy for FL
EP: 10.Sequencing Immunotherapy in the Third-line and Beyond Setting for FL
EP: 11.Unmet Needs in Treating Relapsed/Refractory FL
EP: 12.Current Treatment Options in First-Line MCL
EP: 13.ASH 2023 Updates on Frontline Therapies in MCL
EP: 14.Current Treatment Options in Second-line MCL
EP: 15.Current Treatment Options in Third-line MCL
EP: 16.Sequencing Therapies in the Third-Line and Beyond Setting for MCL
Now Viewing
EP: 17.Future Directions and Unmet Needs in Relapsed/Refractory MCL
Related Videos
Related Content
